Australia markets closed

X4 Pharmaceuticals, Inc. (XFOR)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.1300-0.1600 (-12.40%)
At close: 04:00PM EDT
1.1300 0.00 (0.00%)
Pre-market: 04:06AM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 189.77M
Enterprise value 133.83M
Trailing P/E 5.49
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)3.71
Enterprise value/revenue N/A
Enterprise value/EBITDA -1.41

Trading information

Stock price history

Beta (5Y monthly) 0.46
52-week change 3-23.13%
S&P500 52-week change 321.08%
52-week high 32.5750
52-week low 30.5720
50-day moving average 31.1286
200-day moving average 31.0622

Share statistics

Avg vol (3-month) 32.5M
Avg vol (10-day) 32.9M
Shares outstanding 5167.94M
Implied shares outstanding 6167.94M
Float 8130.2M
% held by insiders 10.83%
% held by institutions 161.32%
Shares short (15 Apr 2024) 412.26M
Short ratio (15 Apr 2024) 42.97
Short % of float (15 Apr 2024) 47.32%
Short % of shares outstanding (15 Apr 2024) 47.30%
Shares short (prior month 15 Mar 2024) 414.22M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 314 Mar 2019
Ex-dividend date 4N/A
Last split factor 21:6
Last split date 314 Mar 2019

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-44.38%
Return on equity (ttm)-161.67%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -107.1M
Net income avi to common (ttm)-101.17M
Diluted EPS (ttm)-0.5700
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)114.22M
Total cash per share (mrq)0.68
Total debt (mrq)58.28M
Total debt/equity (mrq)114.06%
Current ratio (mrq)5.34
Book value per share (mrq)0.31

Cash flow statement

Operating cash flow (ttm)-96.51M
Levered free cash flow (ttm)-59.79M